Language
International Stem Cell CORP SEC 10-K Report — TradingView News

News

HomeHome / News / International Stem Cell CORP SEC 10-K Report — TradingView News
search
RECENT NEWS

Apr 14, 2023

Let’s Go! at Cisco Live 2023: Cisco Unveils Industry

Mar 15, 2023

Leveraging Data for a Connected Supply Chain

Apr 10, 2023

Honda Honors 54 Suppliers in North America for Performance in the Face of Supply Chain Challenges

May 24, 2023

Three beauty trends spotted at Cosme Tokyo 2023

Nov 13, 2023

Manufacturing for millennials: Start

SEND YOUR INQUIRY
SUBMIT

Mar 29, 2025

International Stem Cell CORP SEC 10-K Report — TradingView News

International Stem Cell Corporation (ISCO), a clinical-stage biotechnology company specializing in the development of therapeutic products using proprietary human parthenogenetic stem cells (hpSCs),

International Stem Cell Corporation (ISCO), a clinical-stage biotechnology company specializing in the development of therapeutic products using proprietary human parthenogenetic stem cells (hpSCs), has released its 2024 10-K report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challenges it faces in the competitive biotechnology sector.

Financial Highlights

Business Highlights

Strategic Initiatives

Challenges and Risks

SEC Filing: International Stem Cell CORP [ ISCO ] - 10-K - Mar. 28, 2025

Financial HighlightsProduct Sales:Cost of Sales:Profit Margin:Net Loss:Net Cash Provided by Operating Activities:Business HighlightsRevenue Segments:Product Lines:Research Products:Therapeutic Market Focus:Clinical Trials:Geographical Performance:Future Outlook:Strategic InitiativesTherapeutic Market Initiatives:Biomedical Market Expansion:Capital Management:Future Outlook:Challenges and RisksEarly Stage Development Risks:Financial Risks:Regulatory Risks:Intellectual Property Risks:Market Risks:Operational Risks:Cybersecurity Risks:Economic Risks: